MXPA03010327A - USO DE OSTEOPONTINA PARA TRATAMIENTO Y/O PREVENCIoN DE ENFERMEDADES NEUROLoGICAS. - Google Patents

USO DE OSTEOPONTINA PARA TRATAMIENTO Y/O PREVENCIoN DE ENFERMEDADES NEUROLoGICAS.

Info

Publication number
MXPA03010327A
MXPA03010327A MXPA03010327A MXPA03010327A MXPA03010327A MX PA03010327 A MXPA03010327 A MX PA03010327A MX PA03010327 A MXPA03010327 A MX PA03010327A MX PA03010327 A MXPA03010327 A MX PA03010327A MX PA03010327 A MXPA03010327 A MX PA03010327A
Authority
MX
Mexico
Prior art keywords
osteopontin
prevention
treatment
neurologic diseases
neurologic
Prior art date
Application number
MXPA03010327A
Other languages
English (en)
Inventor
Boschert Ursula
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of MXPA03010327A publication Critical patent/MXPA03010327A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)

Abstract

La invencion se relaciona con el uso de la osteopontina, o de un agonista de la actividad de la osteopontina, para el tratamiento o prevencion de enfermedades neurologicas.
MXPA03010327A 2001-05-17 2002-05-08 USO DE OSTEOPONTINA PARA TRATAMIENTO Y/O PREVENCIoN DE ENFERMEDADES NEUROLoGICAS. MXPA03010327A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01111296 2001-05-17
PCT/EP2002/005081 WO2002092122A2 (en) 2001-05-17 2002-05-08 Use of osteopontin for the treatment and/or prevention of neurologic diseases

Publications (1)

Publication Number Publication Date
MXPA03010327A true MXPA03010327A (es) 2004-02-17

Family

ID=8177366

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03010327A MXPA03010327A (es) 2001-05-17 2002-05-08 USO DE OSTEOPONTINA PARA TRATAMIENTO Y/O PREVENCIoN DE ENFERMEDADES NEUROLoGICAS.

Country Status (27)

Country Link
US (4) US7217687B2 (es)
EP (1) EP1389130B1 (es)
JP (2) JP4417632B2 (es)
KR (1) KR100947424B1 (es)
CN (2) CN1286524C (es)
AT (1) ATE555803T1 (es)
AU (1) AU2002312886B2 (es)
BG (1) BG108337A (es)
BR (1) BR0209812A (es)
CA (1) CA2443964A1 (es)
CZ (1) CZ20033109A3 (es)
EA (1) EA006655B1 (es)
EE (1) EE200300559A (es)
ES (1) ES2387082T3 (es)
HK (1) HK1067051A1 (es)
HR (1) HRP20030840A2 (es)
HU (1) HUP0400005A3 (es)
IL (2) IL158867A0 (es)
MX (1) MXPA03010327A (es)
NO (1) NO20035025D0 (es)
NZ (1) NZ528852A (es)
PL (1) PL211763B1 (es)
SK (1) SK14232003A3 (es)
UA (1) UA85368C2 (es)
WO (1) WO2002092122A2 (es)
YU (1) YU89503A (es)
ZA (1) ZA200307956B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005046719A1 (en) * 2003-11-12 2005-05-26 Yeda Research And Development Co. Ltd. Vaccine and method for treatment of neurodegenerative diseases
WO2002090974A2 (de) * 2001-05-09 2002-11-14 Biovision Ag Verfahren zum nachweis einer progedienten, chronisch-demenziellen erkrankung, zugehörige peptide und nachweisreagenzien
AU2002357748A1 (en) 2001-11-21 2003-06-10 The Board Of Trustees Of The Leland Stanford Junior University Osteopontin-related compositions and methods
CA2489905A1 (en) * 2002-06-25 2003-12-31 Aventis Pharmaceuticals Inc. Osteopontin, oligodendrocytes and myelination
WO2004013311A2 (en) * 2002-08-06 2004-02-12 Diadexus, Inc. Compositions and methods relating to ovarian specific genes and proteins
KR20050119149A (ko) * 2003-03-28 2005-12-20 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. 말초 신경 질환의 치료 및/또는 예방을 위한 클루스테린의용도
RU2379975C2 (ru) * 2003-09-18 2010-01-27 Арла Фудс Амба Добавка в состав для детского питания
US7790687B2 (en) * 2005-02-18 2010-09-07 Proximagen Ltd. Treatment for neurodegeneration
US20060264371A1 (en) * 2005-02-18 2006-11-23 Proximagen Ltd. Treatment
WO2007047465A1 (en) 2005-10-13 2007-04-26 Anthrogenesis Corporation Production of oligodendrocytes from placenta-derived stem cells
EP1870107A1 (en) * 2006-06-23 2007-12-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of inducer of promyelocytic leukemia protein (PML) for treating polyglutamine expansion neurodegenerative diseases
WO2008086449A2 (en) * 2007-01-09 2008-07-17 Oregon Health & Science University Synthetic osteopontin peptides and methods of use
US20100069254A1 (en) * 2008-09-16 2010-03-18 Laree Hiser Cell Culture Model for Demyelination/Remyelination
KR101449100B1 (ko) 2011-04-21 2014-10-13 가톨릭대학교 산학협력단 신경세포 데브리스 제거용 오스테오폰틴
GB2493540A (en) * 2011-08-10 2013-02-13 Follicum Ab Agents for stimulating hair growth in mammals
KR101728808B1 (ko) * 2012-09-28 2017-04-20 한국생명공학연구원 아세카이니드 또는 이의 유도체를 포함하는 근력약화 관련 질환의 예방 또는 치료용 약학적 조성물
WO2016033329A1 (en) * 2014-08-27 2016-03-03 Dana-Farber Cancer Institute, Inc. Intracellular osteopontin regulates the lineage commitment of lymphoid subsets
KR102425326B1 (ko) 2016-05-20 2022-07-25 세다르스-신나이 메디칼 센터 알츠하이머병 및 관련 병태의 치료 또는 예방 방법
CN109996810B (zh) * 2016-11-27 2023-08-22 特里同阿盖亚创新公司 从微藻中纯化重组骨桥蛋白的方法
WO2018202870A1 (en) 2017-05-04 2018-11-08 Follicum Ab Peptides for treatment of diabetes
US11484576B2 (en) 2017-08-15 2022-11-01 The Children's Medical Center Corporation Methods of promoting corticospinal neuronal outgrowth in neuronal lesions using a pro-regenerative human osteopontin fragment
TR201903865A2 (tr) * 2019-03-14 2020-09-21 Bogazici Ueniversitesi Amyotrofi̇k lateral skleroz tedavi̇si̇ i̇çi̇n i̇nterferon kullanimi
WO2021024265A1 (en) * 2019-08-08 2021-02-11 Ramot At Tel-Aviv University Ltd. Methods of treating non-infectious inflammatory disorders
CN111388654A (zh) * 2020-05-22 2020-07-10 南通大学 治疗脊髓损伤的药物、药物试剂盒及方法
EP4159223A1 (en) * 2020-06-02 2023-04-05 The Catholic University Of Korea Industry-Academic Cooperation Foundation Composition comprising osteopontin inhibitor as active ingredient for prevention, alleviation, or treatment of neurodegenerative disease
CN117720620A (zh) * 2023-12-13 2024-03-19 无锡市儿童医院 小分子多肽和其药物组合物、其制药用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69926536T3 (de) * 1998-12-22 2013-09-12 Genentech, Inc. Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung
JP2003517284A (ja) 1999-04-15 2003-05-27 チルドレンズ メディカル センター コーポレーション 免疫応答を変調する方法及び組成物
WO2000064460A2 (en) 1999-04-23 2000-11-02 Sulzer Orthopedics Ltd. Composition for enhancing functional recovery of a mammal from central and/or peripheral nervous system injury of traumatic or pathological origin
JP4027663B2 (ja) * 1999-10-04 2007-12-26 ネクター セラピューティックス エイエル，コーポレイション ポリマー安定化神経ペプチド

Also Published As

Publication number Publication date
EA006655B1 (ru) 2006-02-24
EP1389130B1 (en) 2012-05-02
JP5036761B2 (ja) 2012-09-26
IL158867A (en) 2010-05-17
HRP20030840A2 (en) 2005-08-31
JP2004536058A (ja) 2004-12-02
JP2009191082A (ja) 2009-08-27
US20040235720A1 (en) 2004-11-25
PL367065A1 (en) 2005-02-21
AU2002312886B2 (en) 2007-10-25
IL158867A0 (en) 2004-05-12
HUP0400005A2 (hu) 2004-04-28
EP1389130A2 (en) 2004-02-18
KR20040008176A (ko) 2004-01-28
NZ528852A (en) 2005-12-23
YU89503A (sh) 2006-05-25
CZ20033109A3 (en) 2004-06-16
CN1939538A (zh) 2007-04-04
BR0209812A (pt) 2004-06-01
CA2443964A1 (en) 2002-11-21
ATE555803T1 (de) 2012-05-15
US7297099B2 (en) 2007-11-20
CN1533283A (zh) 2004-09-29
WO2002092122A3 (en) 2003-03-06
NO20035025L (no) 2003-11-12
SK14232003A3 (sk) 2004-05-04
EE200300559A (et) 2004-02-16
JP4417632B2 (ja) 2010-02-17
EA200301253A1 (ru) 2004-06-24
ES2387082T3 (es) 2012-09-13
ZA200307956B (en) 2004-10-13
UA85368C2 (ru) 2009-01-26
HUP0400005A3 (en) 2012-09-28
WO2002092122A2 (en) 2002-11-21
US20070225214A1 (en) 2007-09-27
KR100947424B1 (ko) 2010-03-12
US7217687B2 (en) 2007-05-15
US20080213234A1 (en) 2008-09-04
BG108337A (bg) 2004-12-30
NO20035025D0 (no) 2003-11-12
PL211763B1 (pl) 2012-06-29
US20050176639A1 (en) 2005-08-11
CN1286524C (zh) 2006-11-29
HK1067051A1 (en) 2005-04-01

Similar Documents

Publication Publication Date Title
MXPA03010327A (es) USO DE OSTEOPONTINA PARA TRATAMIENTO Y/O PREVENCIoN DE ENFERMEDADES NEUROLoGICAS.
ZA200204020B (en) Use of anti-CTLA-4-antibodies.
HK1078266A1 (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same
AP2004003002A0 (en) azabicyclic-substituted fused-heteroaryl compoundsfor the treatment of disease.
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
WO2004028454A3 (en) 1, 3, 5-triazines for treatment of viral diseases
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
ZA200306232B (en) Treatment involving DKK-1 or antagonists thereof.
WO2003088748A8 (en) Use of heme oxygenase-1 and products of heme degradation
EP1499309A4 (en) PREVENTION AND TREATMENT OF FUNCTIONAL SOMATIC DISEASES, INCLUDING STRESS-BASED DISEASES
MXPA03008582A (es) Agentes y metodos para tratamiento de cancer.
WO2004084932A3 (en) Use of clusterin for the treatment and/or prevention of peripheral neurological diseases
IL161501A0 (en) Methods of preventing and treating flavivirus infection in animals
ZA200205098B (en) Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2-mediated disorders.
WO2004037168A3 (en) Treatment of pancreatitis with amylin
HUP0302738A2 (hu) SARP-1 alkalmazása scleroderma kezelésére és megelőzésére
ZA200004363B (en) Treatment or prevention of coccidiosis.
IL181713A0 (en) Use of il-17f for the treatment and/or prevention of neurological diseases
WO2003096877A3 (en) Prevention and treatment of streptococcal and staphylococcal infection
IL158967A0 (en) Identifying parasitic fungi of the organism, and treatment thereof
WO2003064394A8 (de) 5-ring heterozyklen zur verwendung als antiviral mittel
AU2003287513A1 (en) INHIBITORS OF Beta-SECRETASE, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF ALZHEIMER'S DISEASE OR MILD COGNITIVE IMPAIRMENT
AU2003278569A8 (en) Methods for identifying antimicrobial agents, the agents identified therewith and methods of using same
YU80003A (sh) Upotreba proteina uk114 ili njegovih fragmenata za tretman i prevenciju endotoksičnog šoka
AU2003298547A8 (en) 2,4,6-triaminopyrimidines for the treatment of depression and/or anxiety

Legal Events

Date Code Title Description
GB Transfer or rights
HC Change of company name or juridical status
FG Grant or registration